The BCR-ABL1 T315I mutation and additional genomic aberrations
are dominant genetic lesions associated with disease
progression in patients with chronic myelogenous leukemia
resistant to tyrosine kinase inhibitor therapy.

J 2013

The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

MALČÍKOVÁ, Jitka, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ et. al.

Basic information

Original name

Name in Czech

Authors

MALČÍKOVÁ, Jitka (203 Czech Republic, guarantor, belonging to the institution), Filip RÁZGA (703 Slovakia, belonging to the institution), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Hana TOŠKOVÁ (203 Czech Republic, belonging to the institution), Ludmila ŠEBEJOVÁ (203 Czech Republic, belonging to the institution), Jana ŠMARDOVÁ (203 Czech Republic, belonging to the institution), Alexandra OLTOVÁ (203 Czech Republic, belonging to the institution), Gabriela VAŇKOVÁ (203 Czech Republic, belonging to the institution), Lenka JURAČKOVÁ (203 Czech Republic, belonging to the institution), Martin TRBUŠEK (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Zdeněk RÁČIL (203 Czech Republic, belonging to the institution)

Edition

Leukemia & Lymphoma, London, Informa Healthcare, Gordon and Breach, 2013, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.605

RIV identification code

RIV/00216224:14740/13:00071791

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.3109/10428194.2012.762649

UT WoS

000323492400044

Keywords in English

BCR-ABL1; T315I; chronic myelogenous leukemia; therapy

Abstract

ORIG CZ

V originále

The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

In Czech

Mutace BCR-ABL1 T315I a další genomové aberace dominantní genetické léze spojené s progresí onemocnění u pacientů s chronickou myeloidní leukémií odolné proti tyrosin kinázy léčbu inhibitorem. Mutace BCR-ABL1 T315I a další genomové aberace dominantní genetické léze spojené s progresí onemocnění u pacientů s chronickou myeloidní leukémií odolné proti tyrosin kinázy léčbu inhibitorem. Mutace BCR-ABL1 T315I a další genomové aberace dominantní genetické léze spojené s progresí onemocnění u pacientů s chronickou myeloidní leukémií odolné proti tyrosin kinázy léčbu inhibitorem.

Files attached

EL_1163539_The_BCR-ABL1.pdf

Request the author's version of the file

Citovat

MALČÍKOVÁ, Jitka, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Hana TOŠKOVÁ, Ludmila ŠEBEJOVÁ, Jana ŠMARDOVÁ, Alexandra OLTOVÁ, Gabriela VAŇKOVÁ, Lenka JURAČKOVÁ, Martin TRBUŠEK, Šárka POSPÍŠILOVÁ, Jiří MAYER and Zdeněk RÁČIL. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. Leukemia & Lymphoma. London: Informa Healthcare, Gordon and Breach, 2013, vol. 54, No 9, p. 2083-2087. ISSN 1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.762649.

@article{1163539,
   author = {Malčíková, Jitka and Rázga, Filip and Jurček, Tomáš and Dvořáková, Dana and Žáčková, Daniela and Tošková, Hana and Šebejová, Ludmila and Šmardová, Jana and Oltová, Alexandra and Vaňková, Gabriela and Juračková, Lenka and Trbušek, Martin and Pospíšilová, Šárka and Mayer, Jiří and Ráčil, Zdeněk},
   article_location = {London},
   article_number = {9},
   doi = {http://dx.doi.org/10.3109/10428194.2012.762649},
   keywords = {BCR-ABL1; T315I; chronic myelogenous leukemia; therapy},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & Lymphoma},
   title = {The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.},
   url = {http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal},
   volume = {54},
   year = {2013}
}

TY  - JOUR
ID  - 1163539
AU  - Malčíková, Jitka - Rázga, Filip - Jurček, Tomáš - Dvořáková, Dana - Žáčková, Daniela - Tošková, Hana - Šebejová, Ludmila - Šmardová, Jana - Oltová, Alexandra - Vaňková, Gabriela - Juračková, Lenka - Trbušek, Martin - Pospíšilová, Šárka - Mayer, Jiří - Ráčil, Zdeněk
PY  - 2013
TI  - The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
JF  - Leukemia & Lymphoma
VL  - 54
IS  - 9
SP  - 2083-2087
EP  - 2083-2087
PB  - Informa Healthcare, Gordon and Breach
SN  - 10428194
KW  - BCR-ABL1
KW  - T315I
KW  - chronic myelogenous leukemia
KW  - therapy
UR  - http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal
L2  - http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal
N2  - The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
ER  -

MALČÍKOVÁ, Jitka, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Hana TOŠKOVÁ, Ludmila ŠEBEJOVÁ, Jana ŠMARDOVÁ, Alexandra OLTOVÁ, Gabriela VAŇKOVÁ, Lenka JURAČKOVÁ, Martin TRBUŠEK, Šárka POSPÍŠILOVÁ, Jiří MAYER and Zdeněk RÁČIL. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. \textit{Leukemia \&{} Lymphoma}. London: Informa Healthcare, Gordon and Breach, 2013, vol.~54, No~9, p.~2083-2087. ISSN~1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.762649.

Detailed Information on Publication Record